Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24371662 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3S1PR5S1PR2PLA2G2A | |
| SCHEMBL24371448 | 0.91 | PLA2G2A (0.48) | S1PR1S1PR3S1PR5S1PR2PLA2G2A | |
| SCHEMBL16574363 | 0.89 | PLA2G2A (0.55) | S1PR1S1PR3S1PR5S1PR2PLA2G2A | |
| SCHEMBL27547888 | 0.80 | TAS1R3 (0.44) | — | |
| SCHEMBL16575605 | 0.77 | PLA2G2A (0.73) | S1PR1S1PR3S1PR5S1PR2PLA2G2A | |
| SCHEMBL19352538 | 0.75 | EPHX1 (0.39) | — | |
| SCHEMBL20830172 | 0.75 | EPHX1 (0.39) | — | |
| SCHEMBL14191546 | 0.74 | DNM1 (0.39) | — | |
| SCHEMBL6532537 | 0.73 | LPAR5 (0.36) | S1PR1S1PR3S1PR5S1PR2PLA2G2A | |
| SCHEMBL10627440 | 0.72 | GPR84 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | S1PR1 1430/4885S1PR3 1893/4885S1PR5 1864/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | S1PR1 378/4885S1PR3 454/4885S1PR5 633/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | S1PR1 1296/4885S1PR3 1462/4885S1PR5 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.